CDMO vs. PTGX, ZNTL, MLTX, DCPH, MNKD, SMMT, OPK, RCUS, ME, and BLU
Should you be buying Avid Bioservices stock or one of its competitors? The main competitors of Avid Bioservices include Protagonist Therapeutics (PTGX), Zentalis Pharmaceuticals (ZNTL), MoonLake Immunotherapeutics (MLTX), Deciphera Pharmaceuticals (DCPH), MannKind (MNKD), Summit Therapeutics (SMMT), OPKO Health (OPK), Arcus Biosciences (RCUS), 23andMe (ME), and BELLUS Health (BLU). These companies are all part of the "pharmaceutical preparations" industry.
Avid Bioservices vs.
Avid Bioservices (NASDAQ:CDMO) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
In the previous week, Protagonist Therapeutics had 11 more articles in the media than Avid Bioservices. MarketBeat recorded 13 mentions for Protagonist Therapeutics and 2 mentions for Avid Bioservices. Protagonist Therapeutics' average media sentiment score of 0.93 beat Avid Bioservices' score of 0.89 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
Avid Bioservices presently has a consensus price target of $22.33, indicating a potential upside of 27.84%. Protagonist Therapeutics has a consensus price target of $35.50, indicating a potential upside of 71.25%. Given Protagonist Therapeutics' higher possible upside, analysts clearly believe Protagonist Therapeutics is more favorable than Avid Bioservices.
Avid Bioservices has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.
Avid Bioservices has a net margin of 82.78% compared to Protagonist Therapeutics' net margin of -291.70%. Avid Bioservices' return on equity of 1.70% beat Protagonist Therapeutics' return on equity.
Avid Bioservices has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Avid Bioservices, indicating that it is currently the more affordable of the two stocks.
99.0% of Avid Bioservices shares are owned by institutional investors. Comparatively, 91.5% of Protagonist Therapeutics shares are owned by institutional investors. 1.9% of Avid Bioservices shares are owned by insiders. Comparatively, 5.3% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Avid Bioservices received 109 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 66.79% of users gave Avid Bioservices an outperform vote while only 60.53% of users gave Protagonist Therapeutics an outperform vote.
Summary
Avid Bioservices beats Protagonist Therapeutics on 10 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CDMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avid Bioservices Competitors List
